Shae E. Fitzpatrick
Shae represents public and private companies in the pharmaceutical, biotechnology, and medical device industries at all stages of development. She advises clients in a variety of corporate and commercial transactions, including mergers and acquisitions, license and collaboration agreements, research-related agreements, securities offerings, and general corporate matters. Shae also has an active pro bono practice in which she serves on the leadership team of the firm’s medical-legal partnership program, in coordination with DotHouse Health, the Dana-Farber Cancer Institute and Medical-Legal Partnership | Boston, to assist patients at Dana-Farber with a range of legal issues.
Prior to joining the firm, Shae served as a law clerk for the Honorable Chief Justice Paul A. Suttell of the Rhode Island Supreme Court. During law school, Shae worked as a student attorney in the Community Enterprise Clinic at the Boston College Legal Assistance Bureau and as an intern in the U.S. Attorney’s Office for the District of Massachusetts. In addition, Shae served as note editor of the Boston College International and Comparative Law Review and president of the Women’s Law Center. Shae was also a Finalist in the Wendell F. Grimes Moot Court competition.
- Represented a global public pharmaceutical company in its acquisition of the surgical assets of a private medical device company.
- Represents Paratek Pharmaceuticals, Inc. in connection with a range of commercial licensing, manufacturing and supply agreements involving its lead antibiotic, omadacycline.
- Represented CAMP4 Therapeutics Corporation, a venture-backed company, in its $30 million Series A financing and continues to represent the company in ongoing general corporate and commercial matters.
- Represented Bain Capital Life Sciences in its $55 million Series D financing and cross-over investment round for Germany biopharmaceutical company InflaRx to advance clinical development of InflaRx’s lead drug candidate IFX-1, a first-in-class anti-human complement factor C5a monoclonal antibody, in chronic inflammatory and auto-immune indications and to advance pre-clinical development of follow-up pipeline molecules. Following the Series D financing, InflaRx underwent a complex, cross-border corporate reorganization from a Germany private company to a Dutch private company and ultimately to a Dutch public company with limited liability, InflaRx N.V. In November 2017, InflaRx N.V. launched its initial public offering raising approximately $100 million.
- Represented Akebia Therapeutics, Inc. in its exclusive license agreement with Vifor Pharma Group, pursuant to which Vifor is granted the exclusive right to distribute Akebia’s Phase III oral anemia drug (vadadaustat) through its network of U.S. dialysis centers.
- Represented Akebia Therapeutics, Inc. in its $865 million global expansion of its collaboration and license agreement with Otsuka Pharmaceutical to develop and commercialize vadadustat in Europe, China and other territories.
- Represented a global public pharmaceutical company in its acquisition of a venture-backed, private medical device company with a platform technology for the neurovascular treatment of complex aneurysms.
- Represented Verax Biomedical Incorporated in multiple equity financings and continues to represent the company in general corporate matters.
- Represented GNS Healthcare, Inc. in equity financings and continues to represent the company in general corporate matters.
- Shae Fitzpatrick, “Setting Its Sights on the Marrakesh Treaty: The U.S. Role in Alleviating the Book Famine for Persons with Print Disabilities,” 37 B.C. Int’l & Comp. L. Rev. 139 (2014) (cited in International Review of Law, Computers & Technology (2015) and Comments before Federal Communications Commission, CG Docket No. 10-213) (November 5, 2014))
- Shae Fitzpatrick, “Cohabiting with the Accused: The Formal Limits of Spousal Privilege Affirmed in Van der Heijden v. Netherlands,” 36 B.C. Int’l & Comp. L. Rev. 1 (2014)